• Home
  • GROUP HOME
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • R&D
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • Quality
  • Investors
    • Financial Management
    • Financial Data
    • Shareholders
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
  • Careers
Firalis
  • About
    • Group CEO
    • Management Team
    • Supervisory Board
    • Scientific Advisory Board
    • Affiliates
    • R&D Partnerships
    • Distributors
    • Quality Standards
    • Location
  • Products
    • MEMORYLINC
    • NEUROLINCS
    • FIMICS
    • ELISA Kits
    • Recombinant Proteins
    • Monoclonal Abodies
    • Clinical Samples
  • R&D
  • Quality
  • Media
    • Press Releases
    • Media News
    • Newsletters
    • Posts
    • All Media
contact

Article on "Arab Health 2016"

Where the Future of Healthcare is on Display

Arab Health is the largest healthcare event in the Middle East, held at the Dubai International Convention & Exhibition Centre from January 25-28, 2016. Firalis SAS is attending Arab Health in order to explore opportunities to establish new collaborations.

Firalis SAS is a privately owned life sciences company, creating novel values via biomarker discovery, development, and regulatory qualifications. The company is mainly, but not exclusively, active in the field of drug safety, cardiovascular, inflammatory, neuro­degenerative and autoimmune diseases. Firalis provides bio-analytical services and biomarker-based products to the pharmaceutical industry, to biotechnology companies, and to universities. The company owes its leading position to a unique network of clinical centers of excellence, established to conduct studies for biomarker qualifications in clinics.

With a comprehensive expertise in the biomarker domain and with cutting-edge laboratory equip­ments, Firalis develops biomarkers and biomarker-based diagnostic kits to improve disease outcomes and patient comfort and to increase therapeutic decisions aiming at reducing healthcare costs.

Firalis has been awarded with several national and inter­national prizes for its innovative approaches. The company is certified by ISO 13485 and ISO 9001 for the development and production of CE-marked assays and certified by ISO 17025 for testing laboratory.

Firalis SAS at Arab Health 2016

 

 

 

 

 

 

 

 

 

To get further information on Firalis Biomarker Services and its capabilities to successfully level up customer's projects, please contact sales@firalis.com

Firalis SAS
35 Rue du Fort
F-68330 Huningue
Phone +33 389 911 320-8
http://www.firalis.com/

13.01.2016

Follow us on LinkedIn